Antimycin A |
|
|
|
|
|
Positive |
|
35 |
Benoxaprofen |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
Myxothiazol |
|
|
|
|
|
Positive |
|
35 |
Bezafibrate |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
Chlorpromazine |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
p < 0.001 |
3 |
Dantrolene |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
Diclofenac |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
decylubiquinol |
19.4 ± 7.17 (female), 25.00 ± 10.30 (male) |
|
zebrafish (adult, 24 wk) |
isolate mitochondria from liver |
isothermal titration calorimetry (ITC) |
Positive |
Kd |
309 |
hexachlorobenzene |
|
|
zebrafish (adult, 24 wk) |
|
complex III activity assay: decylubiquinol-dependent reduction of cytochrome c by mitochondrial complex III. |
Negative |
|
309 |
Antimycin A |
|
|
|
|
|
Positive |
|
185 |
stigmatellin |
|
|
|
|
|
Positive |
|
185 |
Fluconazole |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
ethoxyformic anhydride |
|
|
|
|
|
Positive |
|
70 |
gefitinib |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
atorvastatin |
|
|
|
C2C12 myoblasts |
|
Positive |
|
180 |
Linezolid |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
Cerivastatin |
100uM |
|
|
C2C12 myoblasts |
measured ubiquinol:cytochrome c oxidoreductase activity in broken C2C12 mitochondria after acute statin exposure at a fixed concentration for all compounds |
Positive |
|
180 |
pitavastatin |
100uM |
|
|
C2C12 myoblasts |
measured ubiquinol:cytochrome c oxidoreductase activity in broken C2C12 mitochondria after acute statin exposure at a fixed concentration for all compounds |
Positive |
|
180 |
lovastatin |
100uM |
|
|
C2C12 myoblasts |
measured ubiquinol:cytochrome c oxidoreductase activity in broken C2C12 mitochondria after acute statin exposure at a fixed concentration for all compounds |
Positive |
|
180 |
Simvastatin |
100uM |
|
|
C2C12 myoblasts |
Measured ubiquinol:cytochrome c oxidoreductase activity in broken C2C12 mitochondria after acute statin exposure at a fixed concentration for all compounds. The lactone forms of the indicated statins were included in the assay medium at their cytotoxic EC50 concentration for measurement of their effect on the catalytic capacity. |
Positive |
|
180 |
Metformin |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
tacrolimus |
1 μM |
|
rat |
isolated kidney mitochondria |
Mitochondrial complex III assay (ubiquinol‐cytochrome c oxidoreductase) |
Positive |
30% |
323 |
rapamycin |
1 μM |
|
rat |
isolated kidney mitochondria |
Mitochondrial complex III assay (ubiquinol‐cytochrome c oxidoreductase) |
Positive |
24% |
323 |
Simvastatin |
200uM |
|
bovine |
heart mitochondria |
Reduction of the CIII cytochromes c1 and b was determined spectrophotometrically in bovine heart mitochondria. |
Positive |
p < 0.01 |
180 |
Nefazodone |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
p < 0.01 |
3 |
paroxetine |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
p < 0.001 |
3 |
Myxothiazol |
|
|
|
|
|
Positive |
|
81 |
moas |
|
|
|
|
|
Positive |
|
82 |
azoxystrobin |
|
|
|
|
|
Positive |
|
83 |
oudemansin a |
|
|
|
|
|
Positive |
|
84 |
pravastatin |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
strobilurin a |
|
|
|
|
|
Positive |
|
84 |
cpmb-oxime |
|
|
|
|
|
Positive |
|
84 |
azoxystrobin |
100 mM |
incubated overnight |
bovine |
isolated heart mitochondria |
Measurements of redox potentials of the ISP |
Positive |
|
83 |
famoxadone |
100 mM |
incubated overnight |
bovine |
isolated heart mitochondria |
Measurements of redox potentials of the ISP |
Positive |
|
83 |
Primaquine |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
stigmatellin |
100 mM |
incubated overnight |
bovine |
isolated heart mitochondria |
Measurements of redox potentials of the ISP |
Positive |
|
83 |
uhdbt |
100 mM |
incubated overnight |
bovine |
isolated heart mitochondria |
Measurements of redox potentials of the ISP |
Positive |
|
83 |
hhdbt uhnq |
100 mM |
incubated overnight |
bovine |
isolated heart mitochondria |
Measurements of redox potentials of the ISP |
Positive |
|
83 |
dibromothymoquinone |
100 mM |
incubated overnight |
bovine |
isolated heart mitochondria |
Measurements of redox potentials of the ISP |
Positive |
|
83 |
radicicol |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
NQNO |
|
|
bovine |
isolated heart mitochondria cytochrome bc1 complex |
|
Positive |
|
166 |
sertraline |
|
|
|
|
|
Positive |
|
307 |
Fluoxetine |
|
|
|
|
|
Positive |
|
307 |
Antimycin A |
|
|
bovine |
isolated heart mitochondria cytochrome bc1 complex |
|
Positive |
|
166 |
Rosiglitazone |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
diuron |
|
|
|
|
|
Positive |
|
83 |
NQNO |
|
|
bovine |
isolated heart mitochondria cytochrome bc1 complex |
|
Positive |
|
166 |
Antimycin A |
|
|
|
|
|
Positive |
|
26 |
Simvastatin |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
p < 0.001 |
3 |
ethylxanthate |
|
|
|
|
|
Positive |
|
167 |
bisulfate |
|
|
|
|
|
Positive |
|
167 |
semicarbazide |
|
|
|
|
|
Positive |
|
167 |
Tamoxifen |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
p < 0.001 |
3 |
salicyaldoxime |
|
|
|
|
|
Positive |
|
167 |
3-NPA |
|
|
|
permeabilized LUHMES cells |
Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 |
Positive |
EC25(NA) [Glc/Gal] |
326 |
Antimycin A |
12000 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
Positive |
EC25(NA) [Glc/Gal] |
326 |
azoxystrobin |
3.6 |
|
|
LUHMES (Lund human mesencephalic) cells |
Glc–Gal–NeuriTox assay |
Positive |
EC25(NA) [Glc/Gal] |
326 |
trazodone |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
Myxothiazol |
|
|
bovine |
heart mitochondria |
|
Positive |
|
29 |
Leflunomide |
50 μM |
48 hr |
|
MEF cells |
Mitochondrial Complex III Activity Assay kit(BioVision) |
Positive |
|
295 |
Trovafloxacin |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Negative |
p < 0.05 |
3 |
Paraquat |
250 μM |
5min |
Sprague Dawley rat |
brain cultures |
|
Positive |
|
242 |
Maneb |
30 mg/kg i.p. twice a week/6 weeks |
|
C57BL/6 mice |
|
|
Positive |
|
242 |
Tamoxifen |
26.6 μM |
|
bovine |
heart mitochondria |
Measurement of complex IV activity |
Positive |
IC50 |
3 |
Tamoxifen |
30 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
IC50 |
3 |
Aluminium |
10 mg/kg/day intragastric for 12 weeks |
|
Wistar rats |
|
|
Positive |
|
242 |
paroxetine |
|
|
|
|
|
Positive |
|
35 |
Pioglitazone |
|
|
|
|
|
Positive |
|
35 |
promethazine |
|
|
|
|
|
Positive |
|
35 |
Tamoxifen |
|
|
|
|
|
Positive |
|
35 |
picoxystrobin |
50µM |
|
|
permeabilized LUHMES cells |
Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 |
Positive |
|
326 |
pyraclostrobin |
50µM |
|
|
permeabilized LUHMES cells |
Assessment of the function of individual mitochondrial complexes using Agilent Seahorse XFe24 |
Positive |
|
326 |
Amiodarone |
50 μM |
|
bovine |
heart mitochondria |
Measurement of complex II + III activity |
Positive |
p < 0.001 |
3 |